NIKKEI 225
28,549.50 -255.35 (-0.89%) HANG SENG
26,150.24 +23.31 (+0.09%) CRUDE OIL
84.55 +0.79 (+0.94%) GOLD FUTURES
1,799.40 +3.10 (+0.17%) DOW
35,677.02 +73.92 (+0.21%) BTC-GBP
44,945.76 +463.64 (+1.04%)
Saniona AB (publ) (SANION.ST)
| Previous close | 11.84 |
| Open | 11.90 |
| Bid | 11.56 x 0 |
| Ask | 11.84 x 0 |
| Day's range | 11.60 - 11.90 |
| 52-week range | 11.30 - 27.75 |
| Volume | 53,641 |
| Avg. volume | 172,350 |
| Market cap | 738.647M |
| Beta (5Y monthly) | 0.77 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.88 |
| Earnings date | 18 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 77.50 |
- Globe Newswire
Saniona completes submission of manufacturing data for Tesomet capsules to U.S. FDA
PRESS RELEASE 18 October 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has completed the submission of all information previously requested by the U.S. Food and Drug Administration (FDA) regarding its chemistry, manufacturing and controls (CMC) program for Tesomet capsules. With this submission completed, Saniona expects to be able to initiate its Phase 2b clinical trials for Tesomet before the end of 2021, as planned. Th
- Globe Newswire
Saniona to participate in multiple upcoming virtual investor conferences
PRESS RELEASE 6 October 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it will present at multiple upcoming virtual investor conferences this fall. Details are as follows: Aktiespararna’s Aktiedagen Stockholm 2021Date/Time: 11 October 2021, 19.00 CEST / 1:00 p.m. EDTPresenter: Trista Morrison, Chief Communications OfficerWebcast Link: https://www.aktiespararna.se/aktiviteter/aktiedagen-stockholm-11-oktober-digitalt-evenemang
- Globe Newswire
Saniona appoints Robert Hoffman to Board of Directors as Chair of the Audit Committee
PRESS RELEASE 16 September 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the appointment of Robert E. Hoffman to its board of directors, as resolved at the extraordinary shareholders’ meeting held on September 16, 2021. Hoffman is an experienced financial executive and board member with nearly 30 years of experience and achievements in accounting, finance, fund raising, strategic planning, corporate governance, investor relations
